Common Variable Immunodeficiency clinical trials at UCSF

1 research study open to eligible people

Common variable immunodeficiency is a condition where the immune system does not work well. UCSF is conducting trials to test Abatacept for lung disease linked to this condition. The research focuses on improving care for those with lung complications.

Showing trials for

  • Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

    open to eligible people ages 4 years and up

    There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Funding Source - FDA OOPD

    San Francisco, California and other locations

Our lead scientists for Common Variable Immunodeficiency research studies include .

Last updated: